| Literature DB >> 31117025 |
Xing Shi1,2, Changjun Shao1, Chunxiong Luo3,4, Yanan Chu1, Jian Wang1, Qingren Meng1, Jun Yu1, Zhancheng Gao5, Yu Kang6.
Abstract
Dysbiosis of airway microbiomes has been found in various respiratory diseases, but its molecular details in terms of taxonomic profile, metabolic characteristics, defensive function, and inhabit adaption are far from clear. Shotgun metagenome sequencing provides detailed information for microbes, whereas its application is rather limited in airways due to host DNA contaminants that overwhelm a minute amount of microbial content. Here, we describe a microfluidics-based enrichment device and an emulsion-based whole-genome amplification procedure (MEEA) for the preparation of DNA from sputa for shotgun sequencing in a metagenomics study. The two protocols coupled in MEEA are first separately assayed with mock samples and are both promising in efficiency and bias. The efficiency and consistency of MEEA are further evaluated in six clinical sputum samples against direct sequencing without enrichment, and MEEA enables 2 to 14 times enrichment for microbial reads, which take 14.68% to 33.52% of total reads. The dominant pathogens detected in MEEA are in excellent agreement with those from clinical etiological tests. Meanwhile, MEEA presents much more microbiome complexity and genome information at a strain level than direct sequencing, exhibiting high sensitivity for identifying prophages and DNA viruses. MEEA provides better microbiome profiling than direct sequencing without a preference for specific microorganisms. The more detailed functional and taxonomic characterization of their species constituents, including both bacterium and virus, facilitates metagenomics studies on the pathogenesis of respiratory microbiomes.IMPORTANCE The airway microbial community, which takes important pathogenic roles for respiratory diseases, is far from clear in terms of taxonomy and gene functions. One of the critical reasons is the heavy contamination of host cell/DNA in airway samples, which hinders the subsequent sequencing of the whole genomic contents of the microbial community-the metagenome. Here, we describe a protocol for airway sample preparation which couples a microbe enrichment microfluidic device and a DNA amplification method performed in numerous droplets. When evaluated with mock and clinical sputum samples, the microfluidics-based enrichment device and emulsion-based whole-genome amplification (MEEA) procedure efficiently removes host cells, amplifies the microbial genome, and shows no obvious bias among microbes. The efficiency of MEEA makes it a promising method in research of respiratory microbial communities and their roles in diseases.Entities:
Keywords: emulsion; metagenomics; microfluidic chip; respiratory microbiome
Year: 2019 PMID: 31117025 PMCID: PMC6589435 DOI: 10.1128/mSystems.00198-19
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
FIG 1Overview of the MEEA procedure. Preliquefied sputum sample is injected into the inlet of the enrichment microfluidic chip, and enriched microorganisms are collected from the outlets of side channels. Then total DNA is extracted from the solution, added to MDA reaction buffer to a final concentration of 0.5 pg/μl, and distributed in at least 5 × 105 emulsion droplets when going through the microfluidic cruciform. The DNA templates are amplified with MDA in uniformed droplets. After purification, the amplification product is applied to shotgun metagenome sequencing.
FIG 2Efficient enrichment of microorganisms without bias. (A) Size selection of microspheres. Thermograms of 0.5- to 9-μm fluorescent microspheres before and after microfluidic chip filter (top) and recovery rates of microspheres of various sizes; error bars indicates means ± standard deviations (SDs) (bottom). (B) The recovery rates of six microorganisms after microfluidic chip filter; error bar indicate means ± SDs. (C) Smears of sputum stained by Hoechst 3342 and viewed under a microscope (×200 magnification) before and after microfluidic chip filter. Blue indicates nuclei and human cells. (D) The proportions of nonhuman DNA in six pairs of sputum samples before and after microfluidic enrichment.
FIG 3MEEA reveals greater complexity of airway microbiomes in patients with acute infections. (A) Comparison of sequencing results of MEEA and direct sequencing in a typical example of patient W1. (B) The top 15 species with their abundances calibrated as proportions of reads mapped to corresponding reference genome in all nonhuman sequences using bowtie2.
FIG 4MEEA improves genome assembly. (A) Reads mapped to S. aureus strain V2200 and C. gilardii strain CR3. (B) The distribution of lengths of assembled contigs in sample W1; red and blue bars represent direct and MEEA sequencing, respectively. (C) The GC content and length of each contig in direct (left) and MEEA (right) sequencing. Contigs are assigned to major species indicated by colored dots.
FIG 5An identified S. aureus prophage. (Top) The contig containing the prophage. Curve above the contig represents the reads coverage, and genes flanking the prophage are indicated with blue (positive-strand gene) and red (negative-strand gene) arrows. (Bottom) A circular genome map of the prophage. Genes in the prophage are labeled above, and green bars represent the attachment site on bacterial genome and prophage.
Variant information of HSV-1 in MEEA and direct sequencing from W2
| Genomic position | Reference | Variant | Proportion of variant | Annotation | Amino acid change | |
|---|---|---|---|---|---|---|
| MEEA | Direct | |||||
| 2352 | A | G | 0.254 | ncRNA | ||
| 2367 | A | G | 0.3803 | 0.381 | ncRNA | |
| 8671 | T | G | 0.188 | 0.2667 | Intergenic | |
| 20592 | T | G | 0.0945 | Intergenic | ||
| 24718 | C | T | 0.9453 | Intergenic | ||
| 24719 | C | T | 0.9143 | Intergenic | ||
| 52423 | A | C | 0.1 | UL26, capsid maturation protease | Synonymous | |
| 58440 | T | C | 0.0845 | UL29, single-stranded DNA-binding protein | 3′ UTR | |
| 76235 | G | T | 0.2474 | 0.2045 | UL36, large tegument protein | Leu→Leu |
| 79410 | T | G | 0.6618 | UL36, large tegument protein | Synonymous | |
| 86871 | C | A | 0.173 | 0.1296 | UL39, ribonucleotide reductase subunit | Pro→Glu |
| 117703 | A | C | 0.1308 | Intergenic | ||
| 118164 | A | C | 0.0992 | 0.1875 | Intergenic | |
| 122528 | T | C | 0.0896 | RL2, involved in latency | Arg→Gly | |
| 124007 | T | C | 0.4429 | 0.4167 | RL2, involved in latency | Ser→Gly |
| 124022 | T | C | 0.2188 | RL2, involved in latency | Asp→Gly | |
| 126820 | T | C | 0.3667 | Intergenic | ||
| 134239 | T | G | 0.4358 | 0.4444 | US2, virion protein | Synonymous |
| 135138 | A | G | 0.0667 | US3, serine/threonine protein kinase | 5′ UTR | |
| 135144 | T | G | 0.0809 | US3, serine/threonine protein kinase | 5′ UTR | |
| 138016 | C | T | 0.8413 | Intergenic | ||
| 138017 | C | T | 0.8626 | 0.8182 | Intergenic | |
| 138018 | C | T | 0.811 | 0.7273 | Intergenic | |
| 139636 | T | G | 0.0426 | Intergenic | ||
| 144831 | A | T | 0.1446 | 0.375 | US11, tegument protein US11 | Ser→Thr |
| 144843 | G | T | 0.4762 | 0.3333 | US11, tegument protein US11 | Synonymous |
Primers and probes
| Species | Forward primer | Reverse primer | Probe |
|---|---|---|---|
| EB virus | CCGGTGTGTTCGTATATGGAG | GGGAGACGACTCAATGGTGTA | TGCCCTTGCTATTCCACAATGTCGTCTT |
| GATCTCTTGGTTCTCGC | CCCGCCTTACCACTACCG | TCGATGAAGAACGCAGCGAA | |
| GGAACTGTAACGGCAGCTGATA | CGAACTCGGAAACTCGCATT | TCCTGATCTTCATATCGCGACTCTTGGTG | |
| ATCGTGACCACCTTGATT | TACCAGAAGATCGACATC | CATTATGTTTGCCGGTATCCGTTT | |
| AGCATCCTAAAAAAGGTGTAGAGA | CTTCAATTTTMTTTGCATTTTCTACCA | TTTTCGTAAATGCACTTGCTTCAGGACCA | |
| CCAGCTGCTAAAGTATTAGTAGAAG | TTCACCGTAAGATACTGTGCC | CAGATGCAGTTGAAGGTTATTTAG |
EB, Epstein-Barr.